ERBB2 and non-small cell lung carcinoma: Furthermore, the IMMUNOTARGET registry, which identified HER-2 alterations in 5% (n = 27) of patients with NSCLC, also linked HER-2 perturbations to immunotherapy resistance, with a poor objective response rate to ICI monotherapy (7%) [4].